Blog
KPV peptide: α-MSH(11–13), PepT1 and NF-κB in research
KPV peptide It is a short tripeptide consisting of the amino acids L-lysine, L-proline and L-valine. It corresponds to the C-terminal sequence of the alpha-melanocyte-stimulating hormone (α-MSH) and is used in scientific research to study cellular signaling, NF-κB and MAPK pathways, the peptide transporter PepT1 and experimental models of the immune response.
When interpreting available literature, it is important to distinguish between Full-length α-MSH, the KPV tripeptide itself, modified KPV analogs, and specific research-grade material. The results of one molecular form or experimental model cannot be automatically transferred to another form or a specific commercial batch.
- What is KPV?
- KPV and α-MSH(11–13)
- NF-κB signaling in cell models
- PepT1 and the KPV transport
- MAPK and other signaling mechanisms
- Research on human keratinocytes
- More recent cell data from 2025
- KPV and melanocortin receptors
- Experimental microbiological research
- Level of scientific evidence
- Research-grade KPV and analytical documentation
- What does the available research not show?
- FAQ
- Primary scientific sources
What is KPV peptide?
KPV is an abbreviation formed from the single-letter codes of three amino acids:
Light – Pro – Val
It is a linear tripeptide derived from the C-terminal region of α-MSH. Therefore, it is often referred to in the literature as α-MSH(11–13).
The short sequence allows the use of KPV as an experimental model to investigate which biological properties of longer α-MSH are associated with its C-terminal part.
| Parameter | Research characteristics |
|---|---|
| Name | KPV |
| Sequence | Lys-Pro-Val |
| Length | 3 amino acids |
| Origin of the sequence | C-terminal fragment of α-MSH, amino acids 11–13 |
| Mechanisms studied | NF-κB, MAPK, PepT1 and cellular cytokine signaling |
| Level of evidence | First of all, in vitro and animal experimental models |
| Storage | According to the label and CoA of the specific research-grade batch |
| Determination | Research Use Only (RUO) – laboratory and analytical research |
KPV and α-MSH(11–13)
α-MSH is a 13-amino acid peptide derived from proopiomelanocortin. KPV represents its last three amino acids – positions 11 to 13.
The significance of this sequence was first explored in older experimental studies. In mouse models, α-MSH(11–13) was evaluated for its experimentally induced local response, and the results indicated that part of the biological activity of α-MSH can be maintained even in the short C-terminal fragment.
Primary source:
Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH.
What is important is that it was about an animal experimental model. The results of such a model do not represent clinical evidence in humans.
NF-κB signaling in cell models
NF-κB is a transcriptional regulatory system involved in the cellular response to various cytokines, stress signals, and other experimental stimuli.
In a study published in Human Keratinocytes, scientists examined α-MSH, KPV, and other related peptides after stimulation of cells with TNF-α.
In the used cell model, a reduction in NF-κB/p65 activation was observed with KPV.
Primary source:
Inhibition of TNF-α-stimulated NFκB/p65 in human keratinocytes by α-MSH and related peptides.
The change in NF-κB signaling in cell culture is a mechanistic experimental data. In itself, it does not demonstrate the treatment of inflammatory disease, clinical efficacy, or the safety of KPV in humans.
PepT1 and the KPV transport
One of the most interesting mechanisms studied in KPV is its interaction with a peptide transporter. PepT1.
PepT1 is a membrane transport protein capable of transporting small di- and tripeptides. In a study published in 2008, researchers investigated the transport of KPV in human intestinal epithelial cell lines and in T cells.
Experimental data supported the transport of KPV through PepT1. NF-κB, MAPK, and the expression of selected cytokines were also monitored in the same models.
The research was subsequently supplemented by two mouse experimental models of colitis.
Primary source:
Dalmasso et al. – PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
The title of the original publication uses the term „reduces intestinal inflammation“ because it describes the results of cellular and mouse experiments. However, this title cannot be used as a general health claim for research-grade material.
MAPK and other signaling mechanisms
Along with NF-κB, KPV was also studied in MAPK signaling.
MAPK represents a group of intracellular kinases through which cells respond to extracellular stimuli. In experimental models of PKD, changes in signaling pathways associated with the cytokine response have been evaluated, for example.
Further work also investigated the production of nitric oxide in activated macrophage cells.
In an experimental study with RAW 264.7 macrophages, KPV and its analogues altered the production of NO after stimulation of LPS/IFN-γ cells.
Primary source:
Effects of α-melanotropin C-terminal tripeptide analogues on macrophage NO production.
Research on human keratinocytes
Keratinocytes constitute one of the human cell systems that the KPV was experimentally studied on.
Older studies evaluated, for example, the response of cells after TNF-α stimulation and subsequent activation of NF-κB. The results supported the hypothesis that short C-terminal fragments of α-MSH can influence intracellular signaling mechanisms even in cells that are not melanocytes.
These data are important for cellular and molecular biology, but The experiment on keratinocytes cannot be confused with the clinical result on human skin.
More recent cell data from 2025
In 2025, another study using the human keratinocyte cell line HaCaT was published.
Researchers created an experimental model of exposure of cells to fine dust particles PM10 and subsequently investigated changes in oxidative parameters, cytokine signaling, cell viability, and MAPK/NF-κB mechanisms after exposure to KPV.
In this particular case In vitro models changes in several monitored cellular parameters were recorded, including IL-1β and MAPK/NF-κB signaling.
Primary source:
This is a cellular experiment, and the results cannot be interpreted as a confirmed dermatological or health effect in humans.
KPV and melanocortin receptors
Since KPV is derived from α-MSH, it can be assumed that all its experimental effects must occur through classical melanocortin receptors.
However, experimental data show a more complex picture.
A study examining KPV and its analogs in macrophage and other cell models did not detect classical binding to the studied melanocortin receptors or a typical cAMP response to α-MSH(11–13) itself.
Primary source:
Effects of alpha-melanotropin C-terminal tripeptide analogues on macrophage NO production.
Therefore, it is not appropriate to describe the mechanism of KPV simply by stating that it „activates the melanocortin receptor“. The available data support the study of receptor-independent mechanisms as well.
Experimental microbiological research
CVP and modified C-terminal melanocortin peptides have also been studied in laboratory microbial models.
In one in vitro The researchers evaluated α-MSH, KPV and D-Val analogs against selected gram-positive and gram-negative bacteria.
Antibacterial activity against the tested microorganisms was observed in the laboratory model used.
Primary source:
Antimicrobial action of melanocortin peptides and identification of a novel X-Pro-D/L-Val sequence.
However, the result of laboratory cultivation of microorganisms is not evidence of clinical antimicrobial efficacy nor a reason to use KPV as a health product.
The level of scientific evidence regarding CPV
| Type of evidence | Example | Correct interpretation |
|---|---|---|
| Bunk models | NF-κB, MAPK, cytokines, NO | Mechanistic data from specific cellular systems. |
| Transport models | PepT1 in intestinal cells | Information on the transport of the peptide in the experimental system used. |
| Animal models | Experimental local response and models of colitis | Preclinical results, not an automatic result in humans. |
| Microbial models | Laboratory cultures of bacteria | In vitro biological activity, not clinical antimicrobial efficacy. |
| Research-grade COA | Identity, chromatographic purity and batch quantity | Analytical characterization, not clinical safety or efficacy. |
Research-grade KPV and analytical documentation
The results of the published study describe a specific molecule and a specific experimental system. They do not automatically provide information about the quality of another commercially available research-grade batch.
Therefore, the following are particularly relevant for laboratory PKV:
- the exact identity of the Lys-Pro-Val tripeptide,
- molecular form of the material,
- chromatographic purity,
- molecular identification,
- quantitative determination of quantity,
- batch number or lot number,
- the analytical method used,
- audibility of the COA to a specific sample,
- the storage conditions stated on the label and in the CoA of the specific batch.
More about the evaluation of purity, COA and traceability of research-grade materials can be found in the article 7 criteria for selecting a peptide supplier.
The documentation available for the analyzed batches can be verified in the section COA and analytical documentation.
What does the available research not show?
In the case of KPV, it is important to distinguish between mechanistic and preclinical results and health or therapeutic claims.
The available data by themselves do not show:
- clinical efficacy of CPV in inflammatory diseases in humans,
- the suitability of research-grade PPE for personal or humanitarian use,
- that the results of mouse models apply automatically to humans,
- that the experiment on intestinal cells provides evidence of an effect on the human gastrointestinal system,
- that the results on keratinocytes represent a confirmed effect on human skin,
- that in vitro activity against microorganisms constitutes a clinical antimicrobial effect,
- that the results of modified analogs of KPV automatically apply to the unmodified Lys-Pro-Val,
- that the analytical purity of a particular batch represents evidence of clinical safety or efficacy.
Therefore, it is not appropriate to present KPV with consumer-friendly formulations such as „intestinal peptide“, „treats inflammation“, „restores the skin“, „heals the intestines“, or „antimicrobial therapy“. Such formulations go beyond the level of available experimental evidence.
How to critically read studies on CPV?
It is advisable to verify at each publication:
- whether an unmodified KPV or its analogue was used,
- whether it was a cellular, microbial or animal model,
- which signaling pathway or experimental endpoint was monitored,
- whether PepT1 transport was studied or the cellular response itself,
- whether it is a primary experimental study or an overview article,
- whether the results were confirmed in other independent models.
Such an approach helps to separate the experimental mechanism from a claim that would go beyond the published data.
FAQ – KPV peptide and research
What is KPV peptide?
KPV is a tripeptide with the sequence Lys-Pro-Val. It represents the C-terminal fragment of α-MSH corresponding to amino acids 11–13.
What does α-MSH(11–13) mean?
These are positions 11 to 13 in the 13-amino acid sequence of α-MSH. These three C-terminal amino acids form the KPV.
What mechanisms are being investigated in the KPV?
Published experimental studies examined, for example, NF-κB, MAPK, the production of selected cytokines, nitric oxide, and transport through PepT1.
What is PepT1?
PepT1 is a membrane peptide transporter capable of transporting small di- and tripeptides. Transport of KPV has also been studied in experimental intestinal cell models.
Does KPV bind to classical melanocortin receptors?
Some experimental studies did not detect a classical binding to the studied melanocortin receptors or a typical cAMP response with KPV. Therefore, the mechanism of KPV cannot be simplified to just classical melanocortin receptor signaling.
Are there clinical evidence of CPV in humans?
Most of the available functional data comes from cellular, microbial, and animal experimental models. Such results cannot be automatically interpreted as clinical efficacy in humans.
Is an HPLC purity data sufficient for research-grade KPV?
No. Chromatographic purity is only one parameter. Identity, quantity, molecular form, batch and other analytical data must be evaluated separately.
How is research-grade KPV stored?
Storage conditions should be governed by the data on the label and in the CoA of a specific batch. For laboratory material, the batch-specific technical data of the manufacturer or analytical documentation always take precedence.
You can find more professional articles in the section Research on peptides.
Primary scientific sources
- Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. PubMed
- Inhibition of tumor necrosis factor-alpha stimulates NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and related peptides. PubMed
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PubMed
- Effects of alpha-melanotropin C-terminal tripeptide analogues on macrophage NO production. PubMed
- Sung J, et al. The Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue and Cell. 2025. PubMed
- Antimicrobial action of melanocortin peptides and identification of a novel X-Pro-D/L-Val sequence in Gram-positive and Gram-negative bacteria. Peptides. 2008. PubMed
This article is for informational, educational, and scientific purposes only. The information describes molecular, cellular, microbiological, and preclinical experimental data. It is not medical advice, diagnosis, prevention, or a guide to treatment.
Results observed in cell cultures, microbial systems, or animal models cannot be automatically interpreted as a confirmed clinical, dermatological, gastrointestinal, antimicrobial, or other health effect in humans.
Research-grade KPV and other materials presented on the NEXXUS BIO website are intended solely for laboratory, analytical, and scientific purposes (Research Use Only). They are not intended for human or veterinary use, consumption, personal application, diagnosis, prevention, or treatment.